Silver Book Fact

Delaying the onset and progression of Alzheimer’s disease would reduce the projected number of people with moderate to severe cases of the disase to 4.4 million instead of 10.3 million in 2050.

Alzheimer's Association. Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research. Falls Church, VA: The Lewin Group; 2004

Reference

Title
Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research
Publisher
The Lewin Group
Publication Date
2004
Authors
Alzheimer's Association

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.  
  • Medicaid Costs, 5-Year Delayed Onset  
  • Medicare Costs, Slowed Progression  
  • A study of rasagiline mesylate in Parkinson’s disease patients showed improved motor fluctuations and other Parkinson’s disease symptoms.  
  • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.